Lumito’s technology enables quantification of low abundant cells
Lumito AB (publ) (“Lumito” or the “Company”) today announces new results from its collaboration with Truly Labs AB (“Truly Labs”), demonstrating that Lumito’s tissue analysis technology enables significantly improved detection of low abundant, “rare”, cells compared to conventional staining methods. The results were presented at the Pharma Outsourcing conference, organised by Life Science Sweden, on […]
Lumito strengthens its international presence and participates in Digital Pathology & AI Congress Europe
Lumito AB (publ) (“Lumito” or the “Company”) is this week participating in one of Europe’s leading conferences for digital pathology, image analysis, and AI-driven technologies, the Digital Pathology & AI Congress: Europe in London. The conference gathers representatives from the pharmaceutical industry, CROs, hospital laboratories, academia, and technology companies to discuss developments within digital and […]
Lumito renews its quality certification, ISO 13485:2016
Lumito AB (publ) ("Lumito" or "the Company") today announces that the Company has had its quality certification renewed in accordance with the international standard ISO 13485:2016 – Medical devices – Quality management systems. The audit was carried out by the independent assessment body BSI Group and confirms Lumito’s clear focus on quality, safety, and regulatory […]
Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report
Lumito AB (publ) (“Lumito” or the “Company”) will publish its report for the third quarter of 2025 on 27 November 2025. In connection with the publication, shareholders, investors, and other stakeholders are invited to a webinar on the same day at 14:00 CET. During the session, the Company’s CEO, Sanna Wallenborg, will provide a brief introduction […]
Lumito granted SEK 250,000 business development grant from Region Skåne
Lumito AB (publ) (“Lumito” or “the Company”) announces today that the Company has received a business development grant of SEK 250,000 from Region Skåne. Together with the proceeds from the recently completed rights issue, the funding will primarily be used to accelerate the Company’s commercial development and further strengthen its position in the European market. […]
Conversion of paid subscribed units (BTUs) and first day of trading in warrants of series TO7
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]
Truly Labs AB include Lumito’s tissue analysis technology into its customer offering
Lumito AB (publ) (“Lumito” or the “Company”) today announces that Truly Labs AB (“Truly Labs”), following an evaluation period, has decided to include SCIZYS, Lumito’s product for advanced tissue analysis, in its service offering to research and pharmaceutical clients. The decision follows the pilot study jointly conducted by Lumito and Truly Labs earlier this year. […]
Last day of trading with unit rights in Lumito’s rights issue
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]
Lumito AB and Katana Labs GmbH sign Letter of Intent and enter into a strategic partnership to enhance biomarker detection and quantification
Lumito AB (publ) ("Lumito" or the "Company") today announces that the Company and Katana Labs GmbH (“Katana Labs”) have signed a Letter of Intent (“LOI) formalising a strategic partnership to jointly commercialise an end-to-end, ultra-sensitive immunohistochemistry (IHC) workflow that integrates Lumito’s labelling and scanning technology with Katana Labs’ AI-powered image analysis platform. This is a […]
Investor presentation from Financial Stockholm is now available
Lumito AB’s (publ) ("Lumito" or the "Company") CEO Sanna Wallenborg presented the Company, the ongoing rights issue, and future plans at Financial Stockholm's event in Stockholm yesterday. The presentation is now available on Lumito’s website. On the website, the Company has also published other material connected to the ongoing rights issue. Click here to take […]